Background Changing population-level exposure to modifiable risk factors is a key driver of
changing cancer incidence. Understanding these changes is therefore vital when prioritising …

Background Little is known about the health-related quality of life (HRQOL) of men living with
advanced prostate cancer. We report population-wide functional outcomes and HRQOL in …

Background Little is known about health-related quality of life (HRQOL) following treatment
for bladder cancer (BC). Objective To determine this, we undertook a cross-sectional survey …

Background In the UK, a man’s lifetime risk of being diagnosed with prostate cancer is 1 in 8.
We calculated both the lifetime risk of being diagnosed with and dying from prostate cancer …

… l denotes a principal value of the dielectric tensor and l l, 2 l are its real and imaginary parts.
The imaginary part of the dielectric constant, in the long-wavelength dipole approximation, is …

… Hounsome had full access to all the data in the study and takes responsibility for the …
Hounsome certifies that all conflicts of interest, including specific financial interests and …

Background Little is known about quality of life after bladder cancer treatment. This common
cancer is managed using treatments that can affect urinary, sexual and bowel function. …

Background We wished to examine treatment and outcome patterns in older diffuse large B-cell
lymphoma (DLBCL) patients, with a focus on the effect of route-to-diagnosis to outcome. …

Objective To investigate T umour‐ N ode‐ M etastasis ( TNM ) stage and demographics at
presentation in a very large, contemporary UK cohort of patients with bladder cancer and …

Importance The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) reported
no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality at a …